This company listing is no longer active
Isracann Biosciences Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Isracann Biosciences's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Isracann Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 22 | 0 | -5 | 2 | 0 |
| 31 May 22 | 0 | -5 | 2 | 0 |
| 28 Feb 22 | 0 | -24 | 3 | 0 |
| 30 Nov 21 | 0 | -25 | 4 | 0 |
| 31 Aug 21 | 0 | -25 | 4 | 0 |
| 31 May 21 | 0 | -25 | 5 | 0 |
| 28 Feb 21 | 0 | -19 | 7 | 0 |
| 30 Nov 20 | 0 | -22 | 10 | 0 |
| 31 Aug 20 | 0 | -23 | 11 | 0 |
| 31 May 20 | 0 | -24 | 11 | 0 |
| 29 Feb 20 | -1 | -4 | 9 | 0 |
| 30 Nov 19 | -1 | 0 | 5 | 0 |
| 31 Aug 19 | -1 | -2 | 4 | 0 |
Quality Earnings: Insufficient data to determine if IPOT has high quality earnings.
Growing Profit Margin: Insufficient data to determine if IPOT's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IPOT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare IPOT's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if IPOT's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: IPOT has a negative Return on Equity (0%), as it is currently unprofitable.